Ahmad Aljohmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmad Aljohmani has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Yildiz
Molecular Pharmacology, PZMS, Saarland University, Homburg, Germany
12 shared publications - Markus Bischoff
Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany
4 shared publications Federico Guillermo Gharzia
Molecular Pharmacology, PZMS, Saarland University, Homburg, Germany
3 shared publicationsMatthias Hannig
Clinic of Operative Dentistry, Periodontology and Preventive Dentistry, Saarland University, Homburg, Germany
3 shared publicationsAhmed Mohamed Mostafa Abdrabou
Institute of Medical Microbiology and Hygiene Saarland University Homburg Germany
2 shared publications- Anna Katharina Herta Hirsch
Helmholtz Centre for Infection Research (HZI) − , Campus E8.1
2 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (5) , 1611-1626
Exploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies
Pseudomonas aeruginosa, a major cause of pulmonary infections, poses significant clinical challenges due to its virulence and rising antimicrobial resistance. We investigated the role of LasB, a key virulence factor and elastase of P. aeruginosa, in disrupting the lung epithelial barrier. LasB cleaves the junctional protein E-cadherin, alters Claudin-4 localization, and reduces levels of immunomodulatory cytokines including GM-CSF and G-CSF. Using bronchial and alveolar cell models, we demonstrate that LasB induces dose-dependent barrier damage in both systems. Transcriptomic analysis reveals widespread gene expression changes, including the upregulation of DUSP2 and FGFBP1 associated with stress signaling and immune modulation. LasB inhibitors mitigate barrier disruption and partially restore cytokine levels. In a live bacterial infection model, LasB inhibition supports antibiotic treatment, enhancing bacterial clearance and preserving epithelial integrity. These findings establish LasB as a pivotal factor in P. aeruginosa pathogenesis and highlight the therapeutic potential of antivirulence strategies targeting LasB as promising adjuncts to conventional antibiotics.
- 10 April 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (5) , 1611-1626
Open AccessExploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies
Pseudomonas aeruginosa, a major cause of pulmonary infections, poses significant clinical challenges due to its virulence and rising antimicrobial resistance. We investigated the role of LasB, a key virulence factor and elastase of P. aeruginosa, in disrupting the lung epithelial barrier. LasB cleaves the junctional protein E-cadherin, alters Claudin-4 localization, and reduces levels of immunomodulatory cytokines including GM-CSF and G-CSF. Using bronchial and alveolar cell models, we demonstrate that LasB induces dose-dependent barrier damage in both systems. Transcriptomic analysis reveals widespread gene expression changes, including the upregulation of DUSP2 and FGFBP1 associated with stress signaling and immune modulation. LasB inhibitors mitigate barrier disruption and partially restore cytokine levels. In a live bacterial infection model, LasB inhibition supports antibiotic treatment, enhancing bacterial clearance and preserving epithelial integrity. These findings establish LasB as a pivotal factor in P. aeruginosa pathogenesis and highlight the therapeutic potential of antivirulence strategies targeting LasB as promising adjuncts to conventional antibiotics.
- Open Access
- 6 November 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (2) , 2402060
Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia
Background: Pneumonia caused by viral or bacterial pathogens such as severe acute respiratory syndrome coronavirus 2 or Pseudomonas aeruginosa may result in life-threatening disease with a strong contribution of protease dysregulation. The present study aimed to systematically characterise the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia. Methods: The analysis of coronavirus disease 2019 (COVID-19) and bacterial pneumonia patient samples was combined with in vivo experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies. Results: Hospitalised bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a pre-clinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarisation, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level. Conclusion: Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.
- 6 November 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (2) , 2402060
Open AccessLeukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia
Background: Pneumonia caused by viral or bacterial pathogens such as severe acute respiratory syndrome coronavirus 2 or Pseudomonas aeruginosa may result in life-threatening disease with a strong contribution of protease dysregulation. The present study aimed to systematically characterise the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia. Methods: The analysis of coronavirus disease 2019 (COVID-19) and bacterial pneumonia patient samples was combined with in vivo experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies. Results: Hospitalised bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a pre-clinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarisation, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level. Conclusion: Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.
- Top Cited PapersOpen Access
- 21 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 3285-3301
Biological sex differences in pharmacokinetics and adverse drug reactions
Although physiological and hormonal differences between males and females can significantly alter drug absorption, distribution, metabolism, and excretion (ADME), most current pharmacotherapeutic guidelines remain sex neutral. The chapter aims to elucidate biological sex-specific factors across all pharmacokinetic (PK) phases, subsequent therapeutic efficacy, and adverse drug reactions (ADRs), and to highlight implications for individualized therapy including within-woman variation across the menstrual cycle and other hormonal states. This work is based on an extensive review of current literature and clinical data examining sex-specific variations across all phases of pharmacokinetics. Significant biological sex-related differences were found among all PK phases. Females tend to have slower gastric emptying, higher body fat composition, and lower glomerular filtration rates. CYP3A4 is typically more active in females, while CYP1A2, CYP2D6, and CYP2E1 show greater activity in males. In females, endogenous or exogenous hormonal fluctuation can slightly affect gastric motility, protein binding, and selected CYP activities altering clearance for susceptible drugs. In addition, pregnancy increases plasma volume and glomerular filtration with predictable effects on renally cleared drugs and selected hepatic pathways. These differences influence drug half-life, systemic exposure, and the risk of ADRs. Biological sex is a significant determinant of drug pharmacokinetics. Integrating biological sex-specific data into clinical guidelines is essential to optimize drug efficacy and minimize ADRs. Future research and regulatory action should promote biological sex aware pharmacological practices, encouraging routine inclusion of biological sex analyses in clinical trials. Graphical Abstract
- 21 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 3285-3301
Top Cited PapersOpen AccessBiological sex differences in pharmacokinetics and adverse drug reactions
Although physiological and hormonal differences between males and females can significantly alter drug absorption, distribution, metabolism, and excretion (ADME), most current pharmacotherapeutic guidelines remain sex neutral. The chapter aims to elucidate biological sex-specific factors across all pharmacokinetic (PK) phases, subsequent therapeutic efficacy, and adverse drug reactions (ADRs), and to highlight implications for individualized therapy including within-woman variation across the menstrual cycle and other hormonal states. This work is based on an extensive review of current literature and clinical data examining sex-specific variations across all phases of pharmacokinetics. Significant biological sex-related differences were found among all PK phases. Females tend to have slower gastric emptying, higher body fat composition, and lower glomerular filtration rates. CYP3A4 is typically more active in females, while CYP1A2, CYP2D6, and CYP2E1 show greater activity in males. In females, endogenous or exogenous hormonal fluctuation can slightly affect gastric motility, protein binding, and selected CYP activities altering clearance for susceptible drugs. In addition, pregnancy increases plasma volume and glomerular filtration with predictable effects on renally cleared drugs and selected hepatic pathways. These differences influence drug half-life, systemic exposure, and the risk of ADRs. Biological sex is a significant determinant of drug pharmacokinetics. Integrating biological sex-specific data into clinical guidelines is essential to optimize drug efficacy and minimize ADRs. Future research and regulatory action should promote biological sex aware pharmacological practices, encouraging routine inclusion of biological sex analyses in clinical trials. Graphical Abstract
- Open Access
Dual-domain Flower signaling coordinates extracellular vesicles-mediated fitness selection and cell-intrinsic survival in astrocytes
Cellular fitness surveillance preserves tissue integrity, yet its regulation within the mammalian brain remains poorly understood. We identify a bifurcated mechanism in the transmembrane protein Flower—encoding both survival-promoting (“win”) and apoptosis-inducing (“lose”) isoforms. We demonstrate that astrocytes secrete specialized extracellular vesicles (EVs), termed “fitness vesicles,” carrying Flower to facilitate competitive selection across distal cell populations. The N-terminal Flower domain acts extrinsically via these EVs to drive the elimination of less-fit neighbors. Conversely, the “win“-specific C-terminal domain functions as a cell-intrinsic module; it translocates to the nucleus under stress to repress Caspase-3 and provide resilience. In Alzheimer’s disease (AD) models and human AD brains, Flower-positive astrocytes accumulate around amyloid-β (Aβ) plaques. Under Aβ stress, the “win” isoform reprograms astrocytes toward a neuroprotective state that enhances plaque clearance while ensuring cell-intrinsic survival. Our findings reveal how Flower couples long-range, EV-mediated cellular selection with cell-autonomous protection to coordinate astrocyte quality control and tissue resilience in neurodegeneration.
Open AccessDual-domain Flower signaling coordinates extracellular vesicles-mediated fitness selection and cell-intrinsic survival in astrocytes
Cellular fitness surveillance preserves tissue integrity, yet its regulation within the mammalian brain remains poorly understood. We identify a bifurcated mechanism in the transmembrane protein Flower—encoding both survival-promoting (“win”) and apoptosis-inducing (“lose”) isoforms. We demonstrate that astrocytes secrete specialized extracellular vesicles (EVs), termed “fitness vesicles,” carrying Flower to facilitate competitive selection across distal cell populations. The N-terminal Flower domain acts extrinsically via these EVs to drive the elimination of less-fit neighbors. Conversely, the “win“-specific C-terminal domain functions as a cell-intrinsic module; it translocates to the nucleus under stress to repress Caspase-3 and provide resilience. In Alzheimer’s disease (AD) models and human AD brains, Flower-positive astrocytes accumulate around amyloid-β (Aβ) plaques. Under Aβ stress, the “win” isoform reprograms astrocytes toward a neuroprotective state that enhances plaque clearance while ensuring cell-intrinsic survival. Our findings reveal how Flower couples long-range, EV-mediated cellular selection with cell-autonomous protection to coordinate astrocyte quality control and tissue resilience in neurodegeneration.
- Open Access
- 4 November 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-18
Regulation of ADAM10 activity through microdomain-dependent intracellular calcium changes
A disintegrin and metalloproteinases (ADAMs) are transmembrane proteases that cleave other proteins close to the surface in a process called shedding. The prominent member ADAM10 has been linked to several pathologies such as Alzheimer’s disease, bacterial infection, cancer development and metastasis. Although the regulation of the ADAM10 activity by calcium influx and calmodulin inhibition has been reported, the spatiotemporal regulation of Ca2+-dependent ADAM10 activation and the required source of Ca2+ ions have not been thoroughly studied. In the present study, we observed the rapid Ca2+-dependent activation of ADAM10 in A549 lung carcinoma cells upon stimulation with ionomycin. The calmodulin-inhibitors trifluoperazine and ophiobolin A mediated delayed activation of ADAM10, which apparently did not depend on intracellular Ca2+ in the case of trifluoperazine. Furthermore, the surface translocation and release of ADAM10 in extracellular vesicles exhibited different kinetics and were only partially linked to catalytic activation. Finally, ADAM10 activation was observed after the entry of Ca2+ through certain channels, such as canonical members of transient receptor potential (TRP) channels. Therefore, the opening of particular channels for Ca2+ entry points and subsequent Ca2+ flux as well as the temporal aspects of the consequent increase in Ca2+ levels, must be considered for future therapeutic options involving the increasing or decreasing ADAM10 activity.
- 4 November 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-18
Open AccessRegulation of ADAM10 activity through microdomain-dependent intracellular calcium changes
A disintegrin and metalloproteinases (ADAMs) are transmembrane proteases that cleave other proteins close to the surface in a process called shedding. The prominent member ADAM10 has been linked to several pathologies such as Alzheimer’s disease, bacterial infection, cancer development and metastasis. Although the regulation of the ADAM10 activity by calcium influx and calmodulin inhibition has been reported, the spatiotemporal regulation of Ca2+-dependent ADAM10 activation and the required source of Ca2+ ions have not been thoroughly studied. In the present study, we observed the rapid Ca2+-dependent activation of ADAM10 in A549 lung carcinoma cells upon stimulation with ionomycin. The calmodulin-inhibitors trifluoperazine and ophiobolin A mediated delayed activation of ADAM10, which apparently did not depend on intracellular Ca2+ in the case of trifluoperazine. Furthermore, the surface translocation and release of ADAM10 in extracellular vesicles exhibited different kinetics and were only partially linked to catalytic activation. Finally, ADAM10 activation was observed after the entry of Ca2+ through certain channels, such as canonical members of transient receptor potential (TRP) channels. Therefore, the opening of particular channels for Ca2+ entry points and subsequent Ca2+ flux as well as the temporal aspects of the consequent increase in Ca2+ levels, must be considered for future therapeutic options involving the increasing or decreasing ADAM10 activity.
- Open Access
- 24 September 2024
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 52 (2) , 237-248
Extracellular Release of a Disintegrin and Metalloproteinase Correlates With Periodontal Disease Severity
Aim: Periodontal disease is driven by oral pathogens, including Porphyromonas gingivalis, and the release of inflammatory cytokines. These cytokines (e.g., TNF) or their receptors (e.g., IL‐1R) are substrates of a disintegrin and metalloproteinases (ADAMs). In this study, we aimed to determine the effects of ADAMs on periodontal disease phenotypes.Materials and Methods: Western blot and FRET‐based activity measurements of the gingival crevicular fluid (GCF) of patients were compared with those of infected (P. gingivalis) or cytokine‐stimulated oral keratinocytes and primary human neutrophils, respectively. This was accompanied by an analysis of the released extracellular vesicles and MMP9 activity.Results: In the GCF of patients, ADAM8 protein expression and activity were correlated with disease stage, whereas ADAM10 protein expression was inversely correlated with disease stage. Infection and the resulting cytokine release orchestrated the release of soluble ADAM8 by oral keratinocytes and primary neutrophils as soluble ectodomain and on exosomes, respectively. Furthermore, ADAM8 regulated the release of ADAM10 and MMP9.Conclusion: Dysregulation of cell‐associated and extracellular ADAM proteolytic activity may be an essential regulatory element in the progression of periodontal disease driven by ADAM8. The influence of ADAM8 on disease onset and the evaluation of targeting ADAM8 as a potential and novel local treatment option should be addressed in future translational in vivo studies.
- 24 September 2024
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 52 (2) , 237-248
Open AccessExtracellular Release of a Disintegrin and Metalloproteinase Correlates With Periodontal Disease Severity
Aim: Periodontal disease is driven by oral pathogens, including Porphyromonas gingivalis, and the release of inflammatory cytokines. These cytokines (e.g., TNF) or their receptors (e.g., IL‐1R) are substrates of a disintegrin and metalloproteinases (ADAMs). In this study, we aimed to determine the effects of ADAMs on periodontal disease phenotypes.Materials and Methods: Western blot and FRET‐based activity measurements of the gingival crevicular fluid (GCF) of patients were compared with those of infected (P. gingivalis) or cytokine‐stimulated oral keratinocytes and primary human neutrophils, respectively. This was accompanied by an analysis of the released extracellular vesicles and MMP9 activity.Results: In the GCF of patients, ADAM8 protein expression and activity were correlated with disease stage, whereas ADAM10 protein expression was inversely correlated with disease stage. Infection and the resulting cytokine release orchestrated the release of soluble ADAM8 by oral keratinocytes and primary neutrophils as soluble ectodomain and on exosomes, respectively. Furthermore, ADAM8 regulated the release of ADAM10 and MMP9.Conclusion: Dysregulation of cell‐associated and extracellular ADAM proteolytic activity may be an essential regulatory element in the progression of periodontal disease driven by ADAM8. The influence of ADAM8 on disease onset and the evaluation of targeting ADAM8 as a potential and novel local treatment option should be addressed in future translational in vivo studies.
- Open Access
- 24 September 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Dipeptidic Phosphonates: Potent Inhibitors of Pseudomonas aeruginosa Elastase B Showing Efficacy in a Murine Keratitis Model
The ubiquitous opportunistic pathogen Pseudomonas aeruginosa is responsible for severe infections and notoriously known for acquiring antimicrobial resistance. Inhibiting the bacterium’s extracellular elastase, LasB – a zinc-dependent protease – presents a promising strategy to mitigate its virulence. Within this medicinal chemistry–driven hit-to-lead optimization campaign, a new series of highly potent dipeptidic phosphonates is designed and synthesized following a structure–based drug discovery approach. In vitro and in vivo evaluation reveal beneficial pharmacokinetic profiles, excellent selectivity over human off-targets and good tolerability in murine toxicity studies. Ultimately, the scaffold presented herein demonstrates promising in vivo efficacy in a murine Pseudomonas aeruginosa keratitis model in combination with the antibiotic meropenem.
- 24 September 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDipeptidic Phosphonates: Potent Inhibitors of Pseudomonas aeruginosa Elastase B Showing Efficacy in a Murine Keratitis Model
The ubiquitous opportunistic pathogen Pseudomonas aeruginosa is responsible for severe infections and notoriously known for acquiring antimicrobial resistance. Inhibiting the bacterium’s extracellular elastase, LasB – a zinc-dependent protease – presents a promising strategy to mitigate its virulence. Within this medicinal chemistry–driven hit-to-lead optimization campaign, a new series of highly potent dipeptidic phosphonates is designed and synthesized following a structure–based drug discovery approach. In vitro and in vivo evaluation reveal beneficial pharmacokinetic profiles, excellent selectivity over human off-targets and good tolerability in murine toxicity studies. Ultimately, the scaffold presented herein demonstrates promising in vivo efficacy in a murine Pseudomonas aeruginosa keratitis model in combination with the antibiotic meropenem.
- Open Access
- 19 December 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 365, 969-980
A cell-free, biomimetic hydrogel based on probiotic membrane vesicles ameliorates wound healing
- 19 December 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 365, 969-980
Open AccessA cell-free, biomimetic hydrogel based on probiotic membrane vesicles ameliorates wound healing
- Open Access
Extracellular release of a disintegrin and metalloproteinases orchestrates periodontal disease severity
Periodontal diseases are amongst the most common pathologies worldwide with a high risk for the development of systemic complications. Periodontal disease is driven by oral pathogens such as Porphyromonas gingivalis and the release of inflammatory cytokines. These cytokines (e.g. TNF) or their receptors (IL-1R) are substrates of a disintegrin and metalloproteinases (ADAMs). In a comparative approach, we observed an increase of ADAM8 protein expression and activity in the sulcus fluid of periodontal disease patients correlating with the disease stage. In contrast, the induced ADAM10 expression was decreased. In vitro mechanistic studies revealed that both Porphyromonas gingivalis infection and the resulting cytokine release orchestrated the release of soluble ADAM8 by keratinocytes and neutrophils as soluble ectodomain and on exosomes, respectively. Furthermore, ADAM8 regulated the release of ADAM10 and MMP9, thereby potentially influencing wound healing and tissue destruction. Thus, the dysregulation of the cell-associated and extracellular ADAM proteolytic activity mainly driven by ADAM8 may be an essential regulatory element in periodontal disease onset and progression. This potential as novel local treatment option should be addressed in future translational studies.
Open AccessExtracellular release of a disintegrin and metalloproteinases orchestrates periodontal disease severity
Periodontal diseases are amongst the most common pathologies worldwide with a high risk for the development of systemic complications. Periodontal disease is driven by oral pathogens such as Porphyromonas gingivalis and the release of inflammatory cytokines. These cytokines (e.g. TNF) or their receptors (IL-1R) are substrates of a disintegrin and metalloproteinases (ADAMs). In a comparative approach, we observed an increase of ADAM8 protein expression and activity in the sulcus fluid of periodontal disease patients correlating with the disease stage. In contrast, the induced ADAM10 expression was decreased. In vitro mechanistic studies revealed that both Porphyromonas gingivalis infection and the resulting cytokine release orchestrated the release of soluble ADAM8 by keratinocytes and neutrophils as soluble ectodomain and on exosomes, respectively. Furthermore, ADAM8 regulated the release of ADAM10 and MMP9, thereby potentially influencing wound healing and tissue destruction. Thus, the dysregulation of the cell-associated and extracellular ADAM proteolytic activity mainly driven by ADAM8 may be an essential regulatory element in periodontal disease onset and progression. This potential as novel local treatment option should be addressed in future translational studies.
- Open Access
- 14 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14031
Characterization of the Secreted Acid Phosphatase SapS Reveals a Novel Virulence Factor of Staphylococcus aureus That Contributes to Survival and Virulence in Mice
Staphylococcus aureus possesses a large arsenal of immune-modulating factors, enabling it to bypass the immune system’s response. Here, we demonstrate that the acid phosphatase SapS is secreted during macrophage infection and promotes its intracellular survival in this type of immune cell. In animal models, the SA564 sapS mutant demonstrated a significantly lower bacterial burden in liver and renal tissues of mice at four days post infection in comparison to the wild type, along with lower pathogenicity in a zebrafish infection model. The SA564 sapS mutant elicits a lower inflammatory response in mice than the wild-type strain, while S. aureus cells harbouring a functional sapS induce a chemokine response that favours the recruitment of neutrophils to the infection site. Our in vitro and quantitative transcript analysis show that SapS has an effect on S. aureus capacity to adapt to oxidative stress during growth. SapS is also involved in S. aureus biofilm formation. Thus, this study shows for the first time that SapS plays a significant role during infection, most likely through inhibiting a variety of the host’s defence mechanisms.
- 14 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14031
Open AccessCharacterization of the Secreted Acid Phosphatase SapS Reveals a Novel Virulence Factor of Staphylococcus aureus That Contributes to Survival and Virulence in Mice
Staphylococcus aureus possesses a large arsenal of immune-modulating factors, enabling it to bypass the immune system’s response. Here, we demonstrate that the acid phosphatase SapS is secreted during macrophage infection and promotes its intracellular survival in this type of immune cell. In animal models, the SA564 sapS mutant demonstrated a significantly lower bacterial burden in liver and renal tissues of mice at four days post infection in comparison to the wild type, along with lower pathogenicity in a zebrafish infection model. The SA564 sapS mutant elicits a lower inflammatory response in mice than the wild-type strain, while S. aureus cells harbouring a functional sapS induce a chemokine response that favours the recruitment of neutrophils to the infection site. Our in vitro and quantitative transcript analysis show that SapS has an effect on S. aureus capacity to adapt to oxidative stress during growth. SapS is also involved in S. aureus biofilm formation. Thus, this study shows for the first time that SapS plays a significant role during infection, most likely through inhibiting a variety of the host’s defence mechanisms.